Shire PLC (SHPG) Holdings Lowered by Oak Ridge Investments LLC
Oak Ridge Investments LLC cut its position in Shire PLC (NASDAQ:SHPG) by 9.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 73,488 shares of the biopharmaceutical company’s stock after selling 7,523 shares during the period. Oak Ridge Investments LLC’s holdings in Shire PLC were worth $11,254,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently modified their holdings of the company. Hartford Financial Management Inc. boosted its holdings in shares of Shire PLC by 5.4% in the 2nd quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 32 shares in the last quarter. YorkBridge Wealth Partners LLC boosted its holdings in shares of Shire PLC by 81.7% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 705 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 317 shares in the last quarter. Pacer Advisors Inc. acquired a new position in shares of Shire PLC in the 2nd quarter valued at $171,000. Stephens Inc. AR boosted its holdings in shares of Shire PLC by 22.2% in the 2nd quarter. Stephens Inc. AR now owns 1,256 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 228 shares in the last quarter. Finally, Ingalls & Snyder LLC boosted its holdings in shares of Shire PLC by 10.8% in the 2nd quarter. Ingalls & Snyder LLC now owns 1,284 shares of the biopharmaceutical company’s stock valued at $212,000 after buying an additional 125 shares in the last quarter. Institutional investors and hedge funds own 18.27% of the company’s stock.
A number of analysts recently weighed in on SHPG shares. Liberum Capital upgraded shares of Shire PLC from a “hold” rating to a “buy” rating in a research note on Tuesday. Cantor Fitzgerald set a $222.00 price target on shares of Shire PLC and gave the stock a “buy” rating in a research note on Thursday. Barclays PLC cut shares of Shire PLC from an “overweight” rating to an “equal weight” rating in a research note on Friday, August 11th. Jefferies Group LLC reiterated a “hold” rating and set a $206.00 price target (down previously from $216.00) on shares of Shire PLC in a research note on Wednesday, August 9th. Finally, Royal Bank Of Canada reiterated a “buy” rating and set a $213.00 price target on shares of Shire PLC in a research note on Monday, October 2nd. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and eleven have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $212.18.
Shire PLC (NASDAQ:SHPG) traded up $0.65 on Friday, hitting $145.28. 961,468 shares of the company traded hands, compared to its average volume of 1,210,000. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.98 and a quick ratio of 0.52. Shire PLC has a twelve month low of $137.17 and a twelve month high of $192.15. The firm has a market capitalization of $45,000.00, a PE ratio of 9.63, a PEG ratio of 0.78 and a beta of 1.60.
Shire PLC (NASDAQ:SHPG) last released its earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.64 by $0.17. Shire PLC had a net margin of 10.95% and a return on equity of 14.41%. The business had revenue of $3.70 billion for the quarter. During the same period in the prior year, the business posted $3.17 earnings per share. Shire PLC’s revenue was up 7.1% on a year-over-year basis. research analysts expect that Shire PLC will post 15 earnings per share for the current year.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.